deltatrials
Completed PHASE2 NCT01620242

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

Sponsor: UNICANCER

Conditions Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer
Interventions Cabazitaxel
Updated 6 times since 2017 Last updated: Feb 25, 2021 Started: Apr 30, 2012 Primary completion: Jun 30, 2013 Completion: May 27, 2014

Listed as NCT01620242, this PHASE2 trial focuses on Metastatic Head and Neck Cancer and Recurrent Head and Neck Cancer and remains completed. Sponsored by UNICANCER, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UNICANCER
Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Lille, France
  • • Lyon, France
  • • Nice, France
  • • Paris, France
  • • Villejuif, France